205 results
DEFM14A
IMGN
Immunogen, Inc.
2 Jan 24
Proxy related to merger
4:26pm
of December 29, 2023, are outstanding.
Based on information received from RA Capital Healthcare Fund, L.P. Each share of Company Preferred Stock … , L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. with the SEC on February 14, 2023, reported that the reporting persons each
PREM14A
IMGN
Immunogen, Inc.
21 Dec 23
Preliminary proxy related to merger
4:52pm
on information received from RA Capital Healthcare Fund, L.P. Each share of Company Preferred Stock beneficially owned by RA Capital Management, L.P … Capital Healthcare Fund, L.P. with the SEC on February 14, 2023 reported that the reporting persons each had shared voting and investment power
DEFA14A
EX-2.1
IMGN
Immunogen, Inc.
30 Nov 23
Additional proxy soliciting materials
4:07pm
Healthcare Laws, and there is no civil, criminal, administrative, or other action, subpoena, suit, demand, claim, hearing, proceeding, notice, demand or other … the Company or any of its Subsidiaries related to such Healthcare Laws.
(h) To the knowledge of the Company, no Person has filed against the Company or any
8-K
EX-2.1
IMGN
Immunogen, Inc.
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
Healthcare Laws, and there is no civil, criminal, administrative, or other action, subpoena, suit, demand, claim, hearing, proceeding, notice, demand or other … the Company or any of its Subsidiaries related to such Healthcare Laws.
(h) To the knowledge of the Company, no Person has filed against the Company or any
8-K
EX-1.1
olzzb7 5zv3honhpj
5 May 23
Entry into a Material Definitive Agreement
5:15pm
424B5
667 09oje9zo
5 May 23
Prospectus supplement for primary offering
4:49pm
424B5
gss48mll2sr aj
3 May 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
j0k62m oa
3 May 23
ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer
6:35am
8-K
8vupdl1d8b8vl9b097
2 May 23
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-10.1
hm2n8yn06f0 xx
2 May 23
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-99.1
5p0ar7d11nkqov0s6az3
14 Nov 22
ImmunoGen Announces FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer
5:23pm